- $532.71m
- $289.70m
- $219.79m
- 83
- 42
- 72
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.36 | ||
| Price to Tang. Book | 1.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.76% | ||
| Return on Equity | -14.54% | ||
| Operating Margin | -30.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 51.87 | 62.65 | 94.08 | 137.04 | 219.79 | 237.64 | 257.32 | 57.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
Directors
- Daniel Bradbury NEC (60)
- Derek Maetzold PRE (59)
- Frank Stokes CFO (51)
- Kristen Oelschlager R N COO (53)
- Tobin Juvenal OTH (61)
- Kimberlee Caple DRC (59)
- Ellen Goldberg DRC (47)
- Mara Aspinall IND (58)
- G. Bradley Cole IND (65)
- Joseph Cook IND (50)
- Miles Harrison IND (56)
- David Kabakoff IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 12th, 2007
- Public Since
- July 25th, 2019
- No. of Shareholders
- 132
- No. of Employees
- 610
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 27,587,062
- Address
- 505 S Friendswood Drive, FRIENDSWOOD, 77546
- Web
- https://castlebiosciences.com/
- Phone
- +1 2817969032
- Auditors
- KPMG LLP
Upcoming Events for CSTL
Q1 2024 Castle Biosciences Inc Earnings Call
Castle Biosciences Inc Annual Shareholders Meeting
Castle Biosciences Inc Annual Shareholders Meeting
Q2 2024 Castle Biosciences Inc Earnings Release
Similar to CSTL
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Cerus
NASDAQ Global Market
FAQ
What is the Castle Biosciences share price?
As of Today at 19:05 UTC, shares in Castle Biosciences are trading at $19.31. This share price information is delayed by 15 minutes.
How has the Castle Biosciences share price performed this year?
Shares in Castle Biosciences last closed at $19.31 and the price had moved by -19.61% over the past 365 days. In terms of relative price strength the Castle Biosciences share price has underperformed the S&P500 Index by -33.1% over the past year.
What are the analyst and broker recommendations for Castle Biosciences?
The overall consensus recommendation for Castle Biosciences is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Castle Biosciences dividend yield?
Castle Biosciences does not currently pay a dividend.
Does Castle Biosciences pay a dividend?
Castle Biosciences does not currently pay a dividend.
When does Castle Biosciences next pay dividends?
Castle Biosciences does not currently pay a dividend.
How do I buy Castle Biosciences shares?
To buy shares in Castle Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Castle Biosciences?
As of the previous close price of $19.31, shares in Castle Biosciences had a market capitalisation of $532.71m.
Where are Castle Biosciences shares listed?
Here are the trading details for Castle Biosciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CSTL
What kind of share is Castle Biosciences?
Based on an overall assessment of its quality, value and momentum Castle Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Castle Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Castle Biosciences is $33.11. That is 71.47% above the last closing price of $19.31.
Analysts covering Castle Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.24 for the next financial year.
What is the trend in the Castle Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Castle Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +28.08%.
As of the last closing price of $19.31, shares in Castle Biosciences were trading +1.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Castle Biosciences PE Ratio?
The Castle Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $19.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Castle Biosciences?
Castle Biosciences' management team is headed by:
- Daniel Bradbury - NEC
- Derek Maetzold - PRE
- Frank Stokes - CFO
- Kristen Oelschlager R N - COO
- Tobin Juvenal - OTH
- Kimberlee Caple - DRC
- Ellen Goldberg - DRC
- Mara Aspinall - IND
- G. Bradley Cole - IND
- Joseph Cook - IND
- Miles Harrison - IND
- David Kabakoff - IND